美中嘉和以“医疗+AI”双擎驱动 共筑有温度的医疗生态

Core Viewpoint - Meizhong Jiahe Medical Technology Development Group has taken a significant step in its international strategy by signing a memorandum of cooperation with National Hospital in Indonesia to establish a comprehensive oncology service center, marking a milestone in the company's globalization efforts and enhancing China's high-end medical technology's international influence [1] Group 1: Strategic Collaboration - The partnership aims to create a high-level oncology diagnosis and treatment service platform in Indonesia, addressing the common issue of cancer medical resource shortages in Southeast Asia and providing a replicable "Indonesian model" [1] - Meizhong Jiahe has developed a comprehensive solution that includes advanced technologies such as proton therapy and precision radiotherapy, along with a full-chain empowerment system covering personalized plan design, equipment optimization, clinical quality control, and standardized treatment processes [2] Group 2: Technological Innovation - The introduction of Meizhong Jiahe's self-developed tumor treatment model and AI-assisted diagnosis system signifies a new phase of intelligent empowerment in the collaboration, enhancing local doctors' diagnostic efficiency and accuracy [2] - The digital platform will facilitate cross-border medical collaboration, enabling real-time cooperation between Meizhong Jiahe's expert team and Indonesian doctors for complex case management [2] Group 3: Sustainable Development - The core of the collaboration is not merely technology transfer but building a comprehensive oncology medical service ecosystem in Indonesia and Southeast Asia, utilizing a "sister hospital" model for deep medical personnel exchanges and training [3] - The globalization strategy will unfold in three phases: solidifying regional footholds, building a core ecosystem of medical technology empowerment and AI-driven services, and achieving value co-creation for long-term growth [3] Group 4: Vision for the Future - The company aims to expand into the Southeast Asian market, focusing on delivering patient-centered care and creating a comprehensive oncology medical ecosystem that encompasses diagnosis, treatment, rehabilitation, and research [4]